Heparin resistance can be defined as high doses of unfractionated heparin (UFH), greater than 35,000 IU/day, required to raise the activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) to within therapeutically desired ranges or the impossibility of doing so. The most common pathology responsible is the deficiency of anti-thrombin III (ATIII) deficiency. Other clinically relevant conditions that can present with heparin resistance are congenital deficiencies; use of high doses of heparin during extracorporeal circulation, use of asparaginase therapy and disseminated intravascular coagulation (DIC). Most of these conditions effect the ATIII levels. Patients are typically identified in an acute phase, when determination of the cause of resistance is challenging. We present a case where a patient presented with suspected heparin resistance in an acute phase of sickness, where timely intervention was able to prevent a potentially fatal situation.

**Abbreviations:** Neuroendocrine tumors (NETs), World health Organization (WHO), Radiation therapy (RT)

### 1. Introduction

The use of heparin over the past few decades has proven to be a life-saving treatment for many. It has made battling hypercoagulable states convenient and has helped in the form of a prophylaxis medication for clot prevention. The primary effect of heparin is through its interaction with anti-thrombin III (ATIII) [1]. The anticoagulant effect of ATIII is potentiated by a 1000-fold after its transformation when it is bound to heparin molecule [2]. This inactivates thrombin, thus preventing the conversion of fibrin to fibrinogen, and also inactivates activated coagulation factors IX, X, XI and XII. Heparin resistance becomes a concern when greater than 35,000 IU's/day are required to get a sub-therapeutic or negligible response. In this situation, the question of true resistance versus a pseudo-resistance becomes relevant to be addressed. The most cost-effective and widely used tests to check for therapeutic levels are activated partial thromboplastin time (aPTT) and activated coagulation time (ACT) [3].

Heparin resistance can result from increased heparin-binding protein levels (acute phase reactants), low ATIII levels (most common cause), increased heparin clearance levels (e.g. due to splenomegaly in liver disease), high factor VIII levels and factitious resistance such as when heparin is not connected to the intravenous line. Table 1 outlines some predictors of heparin resistance [4].

ATIII deficiency is the most common cause of resistance as discussed earlier, it is further subdivided into two types, type I deficiency and type II defects as shown in Table 2.

Acquired ATIII deficiency can be secondary to several pathological conditions resulting in reduced blood levels. Most of the associated conditions cause multiple abnormalities of the coagulation cascade and alter levels of both pro and anti-coagulants [9–11]. Table 3 outlines some of the common causes of acquired ATIII deficiency.

Use of heparin can also lower ATIII levels by as much as 30 percent, thought to be secondary to increased clearance of ATIII. This, however, does not increase the risk of thrombosis but can result in reporting of falsely low ATIII levels during the treatment phase with heparin. It is preferred that evaluation and work up for thrombophilia therefore should not be done while undergoing therapy. The two major consequences of low ATIII levels are increased thrombotic risk and insensitivity to heparin.

It has also been observed that surgery and trauma can lead to a modest decrease in the levels of ATIII [15,16]. Major surgery has been associated with a fall in ATIII levels with the levels reaching a nadir around post-operative day 3 followed by rise back to normal around day 5. This decrease in the levels combined with the rise in the acute reactants in the blood can also be a risk factor for thrombus formation and acquired heparin
Acquired anti-thrombin III deficiencies.

- AT activity less than or equal to 60%
- Platelets greater than 300,000
- Age 65 or above
- Increased factor VIII and fibrinogen levels

### Table 1. Predictors of heparin resistance.

1. AT activity less than or equal to 60%
2. Platelets greater than 300,000
3. Age 65 or above
4. Increased factor VIII and fibrinogen levels

### Table 2. Phenotypical types of congenital anti-thrombin III deficiencies.

| Type I deficiency                        | Type II defects                        |
|-----------------------------------------|----------------------------------------|
| - Reduced levels of AT                  | - Functionally defective AT             |
| - Reduced synthesis and or stability    | - Mutations leading to                 |
| secondary to the gene mutations         | - Three subtypes                        |
| (small deletions or insertions, large   |                                        |
| deletion or a single base substitution)  |                                        |
| ● Homozygous cases not reported, Seen   |                                        |
| to be lethal in mice [8].               |                                        |

### Table 3. Acquired anti-thrombin III deficiencies.

#### Causes of Acquired anti-thrombin III deficiencies

1. Disseminated intravascular coagulation (DIC)
2. Acute thrombosis
3. Liver disease (primarily cirrhosis)
4. Nephrotic syndrome
5. Extracorporeal membrane oxygenation (ECMO)
6. Hemodialysis
7. Surgery and trauma (major surgery associated with nadir of ATIII approx. postoperative day 3 with rise back to normal around day 5) [5–7,9–11]
8. Asparaginase therapy, e.g. treatment of ALL patients [18].
9. Oral contraceptives and estrogen use leading to modest decrease in levels [12,13]
10. Pregnancy. Minimal decrease in levels in normal pregnancy with more significant decrease in levels with pregnancy-induced hypertension, preeclampsia or eclampsia [12,14,17].

We present a case where timely intervention was able to prevent complications in a complex medical situation, where the diagnosis of resistance versus pseudo-resistance could have meant the difference between life and death.

### 2. Case description

A 30-year-old African-American male patient presenting to the hospital for trauma injuries to his abdomen. He had sustained a gunshot wound, which necessitated an exploratory laparotomy along with a small bowel resection. The patient had to have an ileocecostomy done. He initially improved but on the third day post operatively he became very short of breath and hypoxic. High flow cannula was initiated and a work up for the possible etiologies of hypoxemia was undertaken. Computed tomographic (CT) scan of the chest with intravenous contrast was performed and was notable for a pulmonary embolism (PE) in third and fourth order segmental branches of the right upper lobe pulmonary artery. Heparin infusion was started for treatment.

The usual protocol with aPTT monitoring, for the dose appropriation of heparin infusion, was initiated. During the following period it was found to be difficult to achieve a therapeutic range for anticoagulation based on the aPTT. During this time he had only been therapeutic once following the transfusion of 50,000 IU/24 h without aPTT being therapeutic. Haematology was consulted for evaluation and guidance.

At the time of evaluation patient was in no acute distress without any significant physical findings except for tachycardia and abdominal distention with midline scar closed with mesh. The former was likely explained with the PE the latter was secondary to the surgery. The trend for aPTT was noted to be in a sinusoidal pattern ranging between 51 and 27. Since the patient had multiple factors because of the acute situation, it was decided to check for factor 10 levels. Also factor VIII levels were checked. Because of the acute trauma to the abdomen it was suspected the factor VIII might be abnormal. His factor VIII levels were 400% (normal range of 50–200%), ATIII 64% (normal range 75–135%), and anti-factor 10a 0.1 IU/ml (normal therapeutic range goal for P.E 0.3–0.7 IU/ml).

Analysis of the factor levels showed that though the levels of the factor VIII were high, which can contribute to apparently low aPTT, the patient was in fact subtherapeutic, even with 50,000 IU/24 h of heparin. This was supported by lab value for the AF 10a, which was subtherapeutic for the treatment of PE. It was also established that levels of aPTT were...
not the ideal method of monitoring for heparin dose appropriation. Rather the monitoring of the AF 10a was a better indicator of the dose requirements for heparin. In his situation, the intervention was simple and required increasing the dose of heparin and monitoring AF 10a to the therapeutic range of 0.3–0.7 IU/ml. His dose was further increased and therapeutic levels achieved soon after.

3. Discussion

Identification of heparin resistance can present a challenge for professionals, especially since the use is usually in an acute situation. Resistance is to be considered a possibility with the heparin requirement of the infusion exceeds 35,000 IU/day. The causes of heparin resistance need to be considered in each individual independently. Most commonly the appropriation of therapy is based on the aPTT. However, the measured value can be misleading in situations that result in elevated factor VIII level and or with the use of heparin itself. In cases of suspected elevation of factor VIII levels, it may be more appropriate to check for plasma concentration of heparin with the AF 10a levels.

The most common cause of heparin resistance is AT deficiency. The condition can be congenital and or acquired. Testing for the deficiency during the acute phase of illness while patient is on heparin infusion can be misleading. Usually the norm is to test for the AT levels several weeks after the patient has recovered from the acute illness and is not on any form of anticoagulation therapy. This allows for the normalisation of the acute phase reactants that might inadvertently affect the AT levels. The differentiation of the type of the AT deficiency may be a little more challenging. Congenital disease usually presents earlier in life compared to an acquired condition. In a cohort of study the mean age of the first thromboembolic event was noted to be 14 years [19]. On the contrary acquired disease usually manifests at an older age and with an associated condition, such as surgery or nephrotic syndrome. Prevalence of hereditary form is in the range of .02–0.2 percent and prevalence in individuals with venous thromboembolism is approximated to be between 1 and 7 percent. Three forms of therapeutic treatments are available for patients. In situations where the AT concentrates are not available the use of fresh frozen plasma (FFP) may have to suffice. The two forms of AT concentrate available are recombinant and plasma derived AT concentrate. The recombinant form is administered as initial intravenous dose followed by a continuous maintenance infusion. Dosing is based on AT activity monitoring. Whereas, plasma-derived AT concentrate is given as an initial intravenous dose over 10–20 min, followed by AT activity levels in 2 h, and subsequent dosing based on levels. The advantage of using the plasma-derived form is its 24 hourly dosing compared to the continuous infusion, which results from its longer half-life of 43–77 h compared to 10 h [20,21]. However the disadvantage is the risk of blood borne diseases. Normal range for AT is considered to be 80–120%, treatment is beneficial when levels run less than 40–60%. If aPTT is low and heparin resistance is suspected it is recommended to check for AT-heparin cofactor assay. Further, AT-heparin cofactor assay is preferred with factor Xa over testing with IIa.

In cases where heparin resistance is a concern AT-heparin cofactor assay provide a more specific method of testing for heparin dosage approximation and the possibility of heparin resistance. This takes into account low aPTT levels that can be the result of other confounding factors [17]. In such situations the presence of acute phase reactants, rise of factor VIII secondary to trauma or surgery and the use of heparin leading to increased clearance, makes the interpretation of laboratory data difficult. It was the combination of similar confounding factors that made the health care professionals suspect heparin resistance in the mentioned case.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

No funding source involved.

References

[1] Maurin N. Heparin resistance and antithrombin deficiency. Med Klin (Munich). 2009 Jun 15;104(6):441–449. [Epub 2009 Jun 16].
[2] Hirsh J, Anand SS, Halperin JL, et al. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001;21:1094–1096.
[3] Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006 Nov;96(5):547–552.
[4] Panicucci F, Sagripanti A, Conte B, et al. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Haemostasis. 1980;9:297.
[5] Fitches AC, Appleby R, Lane DA, et al. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood. 1998;92:4671.
[6] Bock SC, Harris JF, Schwartz CE, et al. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet. 1985;37:32.
[7] Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry. 1988;27:6171.
[8] Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112:19.

[9] Hultin MB, McKay J, Ahlgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost. 1988;59:468.

[10] Bock SC, Silberman JA, Wikoff W, et al. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404–407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemost. 1989;62:494.

[11] Navarro-Fernández J, de la Morena-Barrio ME, Padilla J, et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost. 2016;116:146.

[12] Weenink GH, Kahlé LH, Lamping RJ, et al. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand. 1984;63:57.

[13] Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to post-menopausal women. Thromb Haemost. 1992;68:392.

[14] Raschke RA, Guidry JR, Foley MR. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstetrics Gynecol. 2000 Nov;96(5, Part 2):804–806.

[15] Owings JT, Bagley M, Gosselin R, et al. Effect of critical injury on plasma antithrombin activity: low antithrombin levels are associated with thromboembolic complications. J Trauma Acute Care Surg. 1996 Sept;41(3):396–406.

[16] Schippers HG, Roos J, Meulen FVD, et al. Antithrombin III deficiency in surgical intensive care patients. Thromb Res. 1981 Jan 1–15;21(1–2):73–80.

[17] Cirisano FD, Lee S, Greenspoon JS. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. J Reprod Med. 1996 Mar 01;41(3):191–194.

[18] Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L’asparaginase-induced antithrombin III deficiency. Blood. 1994;83:386–391.

[19] Limperger V, Franke A, Kenet G, et al. Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study. Thromb Haemost. 2014;112:478.

[20] Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med. 1989;87:53S.

[21] Menache D, O’Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood. 1990;75:33.